Clinuvel Pharmaceuticals (ASX:CUV) sign CEO for three more years

Company News

by Rachael Jones

Clinuvel Pharmaceuticals (ASX:CUV) today reported that its CEO Philippe Wolgen will stay with the company for three more years.

As its long-serving key executive, Dr Wolgen has steered the Company since its restructure in 2005 to its current successful position.

Clinuvel’s Head of Remuneration Committee Mr Willem Blijdorp says “Amongst its international peers, CLINUVEL ranks near the median value of total annual remuneration awarded to its CEO.”
Shares in Clinuvel Pharmaceuticals (ASX:CUV) are trading 2.1 per cent lower at $25.48.

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.